PDF(1593 KB)
Efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children: a Meta analysis
ZHOU Jian-Mei, ZHONG Xu-Hui, SHI Xin-Miao, DING Jie
Chinese Journal of Contemporary Pediatrics ›› 2020, Vol. 22 ›› Issue (8) : 860-866.
PDF(1593 KB)
PDF(1593 KB)
Efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children: a Meta analysis
Objective To systematically evaluate the efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children. Methods English and Chinese electronic databases were searched to include the studies on the efficacy and safety of steroid combined with immunosuppressants versus steroid alone in the treatment of primary IgA nephropathy in children. Outcome measures included proteinuria remission rate, urinary protein quantification, incidence of adverse events, estimated glomerular filtration rate, and incidence of renal dysfunction. Review Manager 5.3 software was used for data analysis. Results A total of 7 studies with 381 children were included. The children had moderate to severe proteinuria. The Meta analysis showed that compared with the steroid alone group, the steroid combined with immunosuppressants group achieved a significantly higher rate of proteinuria remission (RR=1.36, 95% CI: 1.19-1.55, P < 0.001) and significantly lower urinary protein quantification (SMD=-0.82, 95% CI: -1.23 to -0.41, P < 0.001). There was no significant difference in the incidence rate of adverse events between the two groups (RR=1.28, 95% CI: 0.92-1.77, P=0.14). Conclusions The current evidence shows that for children with primary IgA nephropathy who have moderate to severe proteinuria, steroid combined with immunosuppressants has a better effect than steroid alone and does not increase the incidence rate of adverse events.
Primary IgA nephropathy / Steroid / Immunosuppressant / Meta analysis / Child
[1] Jiang M, Xiao Z, Rong L, et al. Twenty-eight-year review of childhood renal diseases from renal biopsy data:a single centre in China[J]. Nephrology (Carlton), 2016, 21(12):1003-1009.
[2] Santangelo L, Netti GS, Giordano P, et al. Indications and results of renal biopsy in children:a 36-year experience[J]. World J Pediatr, 2018, 14(2):127-133.
[3] Nie S, He W, Huang T, et al. The spectrum of biopsy-proven glomerular diseases among children in China:a national, cross-sectional survey[J]. Clin J Am Soc Nephrol, 2018, 13(7):1047-1054.
[4] Wyatt RJ, Kritchevsky SB, Woodford SY, et al. IgA nephropathy:long-term prognosis for pediatric patients[J]. J Pediatr, 1995, 127(6):913-919.
[5] 全国儿童常见肾脏病诊治现状调研工作组. 中国儿童IgA肾病治疗现状多中心回顾性研究[J]. 中华儿科杂志, 2013, 51(7):486-490.
[6] Chapter 10:immunoglobulin A nephropathy[J]. Kidney Int Suppl (2011), 2012, 2(2):209-217.
[7] 中华医学会儿科学分会肾脏学组. 原发性IgA肾病诊治循证指南(2016)[J]. 中华儿科杂志, 2017, 55(9):643-646.
[8] Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials[J]. Dement Geriatr Cogn Disord, 2001, 12(3):232-236.
[9] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605.
[10] 胡子静. 霉酚酸酯治疗儿童IgA肾病(肾病综合征型)的临床疗效及安全性研究[D]. 沈阳:中国医科大学, 2017.
[11] 唐筠. CsA联合泼尼松对小儿IgA肾病的疗效及对IL-18、ICAM-1的影响[J]. 西南国防医药, 2016, 26(11):1239-1241.
[12] 朱冰冰. 霉酚酸酯与激素联用对IgA肾病患儿的临床疗效及代谢指标的影响[J]. 中国医药导报, 2014, 11(23):76-79.
[13] 郭庆寅. 霉酚酸酯联合激素治疗小儿IgA肾病疗效观察[J]. 广东医学, 2010, 31(7):902-903.
[14] 陈椰, 邓会英, 谭梅, 等. 雷公藤多甙治疗儿童IgA肾病的临床观察[J]. 广东医学, 2018, 39(z1):252-253.
[15] Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy:a randomized, controlled trial[J]. Clin J Am Soc Nephrol, 2006, 1(3):511-517.
[16] Kawasaki Y, Hosoya M, Suzuki J, et al. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy[J]. Am J Nephrol, 2004, 24(6):576-581.
[17] Uzu T, Harada T, Ko M, et al. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria[J]. Clin Exp Nephrol, 2003, 7(3):210-214.
[18] Coppo R, Peruzzi L, Amore A, et al. IgACE:a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria[J]. J Am Soc Nephrol, 2007, 18(6):1880-1888.
[19] Song YH, Cai GY, Xiao YF, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy:a meta-analysis[J]. BMC Nephrol, 2017, 18(1):61.
[20] Du B, Jia Y, Zhou W, et al. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy:an update meta-analysis[J]. BMC Nephrol, 2017, 18(1):245.
[21] Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy[J]. J Am Soc Nephrol, 2010, 21(10):1783-1790.
[22] Floege J, Eitner F. Current therapy for IgA nephropathy[J]. J Am Soc Nephrol, 2011, 22(10):1785-1794.
[23] Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy:recent insight from genetic studies[J]. Annu Rev Med, 2013, 64:339-356.
